Investment Thesis
Lyra Therapeutics faces severe financial distress with negative stockholders' equity of -$10.7M, indicating the company is technically insolvent. Revenue has collapsed 74% YoY to just $398K while operating losses remain substantial at -$31M, demonstrating a complete absence of viable business operations or revenue generation.
Strengths
- Maintains $15.9M in cash reserves providing short-term runway
- Current ratio of 1.71x indicates adequate short-term liquidity relative to current liabilities
- Limited insider selling activity with only 2 Form 4 filings in last 90 days suggests management confidence or constraint
Risks
- Negative stockholders' equity of -$10.7M indicates technical insolvency and existential financial distress
- Revenue collapse of 74% YoY combined with -$31M operating loss demonstrates business model failure
- Negative operating cash flow of -$28.9M with cash burn rate unsustainable even with current cash reserves; company has approximately 6.6 months of runway
- Total liabilities exceed total assets by $10.7M creating structural balance sheet insolvency
- Extreme operating margin of -7794.5% and net margin of -7266.1% indicate zero path to profitability
Key Metrics to Watch
- Monthly cash burn rate and estimated cash runway
- Revenue trends for stabilization or continued deterioration
- Debt restructuring announcements or covenant violations
- Insider transactions indicating confidence or exit activity
- Quarterly operating cash flow for persistence of negative trends
Financial Metrics
Revenue
398.0K
Net Income
-28.9M
EPS (Diluted)
$-18.62
Free Cash Flow
-29.0M
Total Assets
36.1M
Cash
15.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-7,794.5%
Net Margin
-7,266.1%
ROE
N/A
ROA
-80.1%
FCF Margin
-7,280.2%
Balance Sheet & Liquidity
Current Ratio
1.71x
Quick Ratio
1.71x
Debt/Equity
N/A
Debt/Assets
129.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-01T11:52:11.006992 |
Data as of: 2025-12-31 |
Powered by Claude AI